

### REMARKS

Claims 1-26, 41-71, and 73-82 are pending in the application. Claims 27-40 and 72 were previously withdrawn from consideration or canceled. Claims 1, 2, 16-26, 71, 80, and 81 have been allowed. Claims 74 and 75 have been objected to for being dependent on a rejected base claim.

In the Amendments, Claims 3-15 and 41-70, which were previously withdrawn, and Claims 76-79 have been canceled. Claim 1 has been amended to add a semicolon (;) after "B is CH<sub>2</sub>CH<sub>2</sub>". Claims 73 and 82 have been amended to delete the terms "neuroprotection", "neurodegeneration", "inflammation", and "substance abuse". Claim 82 also has been amended to add a period (.) at the end of the claim. Claims 74 and 75 have been amended to present the claims in independent form. It is respectfully submitted that all amendments remove issues for appeal and further facilitate allowance of the application in accordance with the guidelines set forth in 37 C.F.R. § 1.116. Entry of the Amendments is respectfully requested.

Claims 73 and 82 have been rejected for the reasons stated in the Office Action dated June 8, 2007 with respect to the terms "neuroprotection", "neurodegeneration", "inflammation", and "substance abuse". Applicants traverse the rejection and respectfully request reconsideration of the application in view of the Amendments.

Claims 73 and 82 have been amended to delete recitations of the terms object to, such as neuroprotection, neurodegeneration, inflammation, and substance abuse. It is respectfully submitted the rejection of Claims 73 and 82 has been rendered moot in light of the Amendments.


Claims 76-79 also were rejected in the Office Action dated June 8, 2007, however, Claims 76-79 presently have been deleted to further prosecution and facilitate allowance of the application. Applicants reserve the right to file divisional applications on any non-pending or non-elected subject matter.

Accordingly, it is believed that the application is in a condition for allowance and notification of the same is respectfully requested. For the convenience of the Examiner, a

complete set of the claims is provided herewith in accordance with the guidelines for the revised format of amendments in view of 37 C.F.R. § 1.121. Should the Examiner have questions or concerns regarding the foregoing, she is respectfully invited to contact the undersigned by telephone at the phone number provided below to facilitate the prosecution of the application.

ABBOTT LABORATORIES  
Customer No. 23492  
Telephone: (847) 937-8272  
Facsimile: (847) 938-2623

Respectfully submitted,  
*Schrimpf, et al.*



Portia Chen  
Registration No. 44,075  
Attorney for Applicants